Approaches to Improve Chemically Defined Synthetic Peptide Vaccines
Progress made in peptide-based vaccinations to induce T-cell-dependent immune responses against cancer has invigorated the search for optimal vaccine modalities. Design of new vaccine strategies intrinsically depends on the knowledge of antigen handling and optimal epitope presentation in both major...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00884/full |
| _version_ | 1819141500720644096 |
|---|---|
| author | Brett J. Hos Elena Tondini Sander I. van Kasteren Ferry Ossendorp |
| author_facet | Brett J. Hos Elena Tondini Sander I. van Kasteren Ferry Ossendorp |
| author_sort | Brett J. Hos |
| collection | DOAJ |
| description | Progress made in peptide-based vaccinations to induce T-cell-dependent immune responses against cancer has invigorated the search for optimal vaccine modalities. Design of new vaccine strategies intrinsically depends on the knowledge of antigen handling and optimal epitope presentation in both major histocompatibility complex class I and -II molecules by professional antigen-presenting cells to induce robust CD8 and CD4 T-cell responses. Although there is a steady increase in the understanding of the underlying mechanisms that bridges innate and adaptive immunology, many questions remain to be answered. Moreover, we are in the early stage of exploiting this knowledge to clinical advantage. Several adaptations of peptide-based vaccines like peptide-adjuvant conjugates have been explored and showed beneficial outcomes in preclinical models; but in the clinical trials conducted so far, mixed results were obtained. A major limiting factor to unravel antigen handling mechanistically is the lack of tools to efficiently track peptide vaccines at the molecular and (sub)cellular level. In this mini-review, we will discuss options to develop molecular tools for improving, as well as studying, peptide-based vaccines. |
| first_indexed | 2024-12-22T11:55:27Z |
| format | Article |
| id | doaj.art-2f7e95ac110044a39d4bd4866a4252dd |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T11:55:27Z |
| publishDate | 2018-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2f7e95ac110044a39d4bd4866a4252dd2022-12-21T18:26:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-04-01910.3389/fimmu.2018.00884366919Approaches to Improve Chemically Defined Synthetic Peptide VaccinesBrett J. Hos0Elena Tondini1Sander I. van Kasteren2Ferry Ossendorp3Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, NetherlandsDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, NetherlandsLeiden Institute of Chemistry, The Institute for Chemical Immunology, Leiden University, Leiden, NetherlandsDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, NetherlandsProgress made in peptide-based vaccinations to induce T-cell-dependent immune responses against cancer has invigorated the search for optimal vaccine modalities. Design of new vaccine strategies intrinsically depends on the knowledge of antigen handling and optimal epitope presentation in both major histocompatibility complex class I and -II molecules by professional antigen-presenting cells to induce robust CD8 and CD4 T-cell responses. Although there is a steady increase in the understanding of the underlying mechanisms that bridges innate and adaptive immunology, many questions remain to be answered. Moreover, we are in the early stage of exploiting this knowledge to clinical advantage. Several adaptations of peptide-based vaccines like peptide-adjuvant conjugates have been explored and showed beneficial outcomes in preclinical models; but in the clinical trials conducted so far, mixed results were obtained. A major limiting factor to unravel antigen handling mechanistically is the lack of tools to efficiently track peptide vaccines at the molecular and (sub)cellular level. In this mini-review, we will discuss options to develop molecular tools for improving, as well as studying, peptide-based vaccines.http://journal.frontiersin.org/article/10.3389/fimmu.2018.00884/fullpeptide vaccinationclick chemistryantigen presentationintracellular processingtargeted vaccinationtumor immunology |
| spellingShingle | Brett J. Hos Elena Tondini Sander I. van Kasteren Ferry Ossendorp Approaches to Improve Chemically Defined Synthetic Peptide Vaccines Frontiers in Immunology peptide vaccination click chemistry antigen presentation intracellular processing targeted vaccination tumor immunology |
| title | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines |
| title_full | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines |
| title_fullStr | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines |
| title_full_unstemmed | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines |
| title_short | Approaches to Improve Chemically Defined Synthetic Peptide Vaccines |
| title_sort | approaches to improve chemically defined synthetic peptide vaccines |
| topic | peptide vaccination click chemistry antigen presentation intracellular processing targeted vaccination tumor immunology |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00884/full |
| work_keys_str_mv | AT brettjhos approachestoimprovechemicallydefinedsyntheticpeptidevaccines AT elenatondini approachestoimprovechemicallydefinedsyntheticpeptidevaccines AT sanderivankasteren approachestoimprovechemicallydefinedsyntheticpeptidevaccines AT ferryossendorp approachestoimprovechemicallydefinedsyntheticpeptidevaccines |